Cover Image
市場調查報告書

巴西藥品市場展望:2017-2027年

Brazilian Pharmaceutical Market Outlook 2017-2027: Originator, Generic, OTC, CNS, Cardiovascular, Gastrointestinal, Metabolic, Oncology, Infectious Diseases, Domestic Manufacturers and International Drug Companies

出版商 Visiongain Ltd 商品編碼 290179
出版日期 內容資訊 英文 181 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
巴西藥品市場展望:2017-2027年 Brazilian Pharmaceutical Market Outlook 2017-2027: Originator, Generic, OTC, CNS, Cardiovascular, Gastrointestinal, Metabolic, Oncology, Infectious Diseases, Domestic Manufacturers and International Drug Companies
出版日期: 2017年08月18日 內容資訊: 英文 181 Pages
簡介

巴西藥品市場2016年達264億美元、調查前期預計以7.6%成長率變化。2016年原廠品牌藥佔市場最大佔有率、調查後期預計將被學名藥藥品取代最大佔有率。

本報告針對巴西藥品市場調查、提供整體市場動向、種類分類詳細動向、收益額、市場佔有率變化與預測、國內、海外發展商、製造商、販售業者預測、競爭情況。

第1章 調查概要

第2章 巴西藥品市場:介紹

  • 巴西藥品市場概要
  • 學名藥藥品區分重要性持續增加
  • CNS (中樞神經系) 是最大的治療領域
  • 四家前十大國內企業

第3章 巴西市場重要性

  • 世界第8名的巴西經濟
  • 世界第8名的藥品市場
  • 拉丁美洲最大藥品市場
  • 巴西是藥品新興國家市場 (Pharmerging) BRIC市場的一部分

第4章 巴西藥品市場組織

  • ANVISA:相當於巴西FDA的主要組織
  • 其他重要機構
  • SUS (統一保健醫療系統):世界最大公共醫療制度之一
  • 25%人口使用私人醫療機構
  • 私人保健市場成長但保險業者成本上升
  • 新藥價調整制度的引進
  • RENAME Drug補助系統與藥局 (Farmacia) 受歡迎
  • 巴西藥局的緊密網絡
  • 批發與零售部門整合中
  • Panpharma為最大型批發
  • 最大混合批發企業Profarma
  • Raia Drogasil為零售領導者
  • 巴西行銷支出近50億美元

第5章 巴西醫療地區間的主要差異

  • 各地規模與經濟情況
  • 東南部:巴西最富裕人口也最多的地區
  • 南部:最小的地區、但GDP第2高
  • 東北部:藥品市場佔有率第2高
  • 北部:最大最貧窮的地區
  • 中西部:首都所在的內陸地區、人口最少

第6章 巴西藥品市場詳情:產品分類

  • 市場專利處方藥、學名藥與OTC區分預測
  • 原始製藥預測將被學名藥追過
  • 學名藥區分預測
  • 巴西生物製劑市場
  • OTC區分預測

第7章 巴西市場治療領域

  • CNS、心血管、消化/代謝、癌症、感染症與其他治療領域
  • 非傳染性疾病增加
  • CNS疾病市場預測
  • 心血管治療領域市場預測
  • 消化管/代謝治療領域預測
  • 癌症治療藥市場預測
  • 感染症治療領域預測
  • 其他治療領域

第8章 巴西市場國內企業

  • 巴西醫前十大藥品企業
  • 跨國企業依然支配大部分市場
  • 政府獎勵活化國內市場
  • 國內企業支配70%學名藥品市場
  • EMS:巴西最大藥品企業
  • Hypermarcas:OTC與品牌學名藥品領導
  • Medley:Sanofi傘下的學名藥企業
  • Ache:巴西最大收購目標
  • Eurofarma:佔拉丁美洲90%農園的國內前4大企業
  • Teuto:經營拉丁美洲最大的製藥複合企業
  • Biolab Farmaceutica:最大心臟病治療藥廠
  • Cristalia:拉丁美洲最大麻醉藥製造商
  • Libbs:癌症治療中心
  • Uniao Quimica:巨大的年度生產力
  • Laboratorio Daudt Oliveira 與 Hebron、其他國內企業
  • 與生物仿製藥的合作

第9章 巴西市場跨國企業

  • 巴西10大跨國藥品企業
  • 受矚目的M&A活動
  • Sanofi
  • Novartis
  • Roche
  • Merck & Co.
  • Pfizer
  • 武田藥品工業
  • Bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Merck KGaA
  • 其他知名跨國企業
  • 跨國企業在巴西主要學名藥品市場有競爭力嗎
  • 巴西未來的藥品研究

第10章 巴西藥品市場定性分析

  • SWOT分析(強、弱、機會與威脅)
  • STEP分析(社會、技術、經濟與政治因素)

第11章 調查、分析ソ結論

  • 巴西市場成長超越其他先進國家
  • 學名藥品最急速成長分類與預測
  • 技術轉移促進國內創藥
  • 學名藥品:提供跨國企業代替選擇
  • 癌症治療:最大成長領域
  • 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0226

The Brazilian Pharmaceutical market was valued at $26.40bn in 2016. Visiongain forecasts this market to increase at a CAGR of 7.6% in the first half of the forecast period. Originator drugs held the largest market share in 2016, this trend however will change in the second half of the forecast period where we predicted that Generic drugs will take over the lead.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 181-page report you will receive 107 charts - all unavailable elsewhere.

The 181-page report provides clear detailed insight into the Brazilian Pharmaceutical market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Brazilian Pharmaceutical Market forecasts from 2017-2027
  • Brazilian Pharmaceutical Market forecasts from 2017-2027, by segment:
  • Originator Drugs
  • Generic Drugs
  • OTC
  • Brazilian Pharmaceutical Market forecasts from 2017-2027, by therapeutic area:
  • CNS
  • Cardiovascular
  • Gastrointestinal/Metabolic
  • Oncology
  • Infectious Disease

image1

  • Leading Domestic Companies in the Brazilian Pharmaceutical Market:
  • EMS
  • Hypermarcas
  • Medley
  • Eurofarma
  • Aché
  • Cristalia
  • Teuto
  • Libbs
  • Biolab
  • União Química
  • Leading Multinational Companies in the Brazilian Pharmaceutical Market:
  • Novartis
  • Sanofi
  • Roche
  • Merck & Co.
  • Pfizer
  • Takeda
  • Bayer
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Astra Zeneca
  • SWOT and STEP Analysis of the Brazilian Pharmaceutical market
  • This report also discusses:
  • The Brazilian healthcare environment, covering important institutional bodies and agencies, surveying the regulatory system, analyzing the balance between public and private healthcare provision and looking at the wholesale and distribution landscape
  • Regional variations within Brazil, with profiles of each region and an analysis of their healthcare challenges and opportunities
  • Brazilian Biologics Market, which includes qualitative and quantitative analysis.

Visiongain's study is intended for anyone requiring commercial analyses for the Brazilian Pharmaceutical market and the leading companies competing in that country. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Brazil: Pharmaceutical Market Overview
  • 1.2 Brazilian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Main Questions Answered by This Survey
  • 1.6 Who is Our Report For?
  • 1.7 Research and Analysis Methods
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Some Associated Reports
  • 1.10 About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market

  • 2.1 The Brazilian Pharmaceutical Market Overview
  • 2.2 Generics Segment Continues to Grow in Importance
  • 2.3 Central Nervous System Related Disorders- The Largest Therapeutic Area in 2016
  • 2.4 Four Domestic Companies in the Top Ten in 2016

3. The Significance of the Brazilian Market

  • 3.1 Brazilian Economy is the Eight Largest in the World
  • 3.2 Brazil is the Eighth Largest Pharmaceutical Market
  • 3.3 Brazil is the Largest Market in Latin America
  • 3.4 Brazil Qualifies as a 'Pharmerging' Country and one of the BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market

  • 4.1 ANVISA - Brazil's Equivalent of the FDA
  • 4.2 Other Influential Organisations
  • 4.3 SUS - One of the World's Largest Public Health Systems
  • 4.4 Private Healthcare Accessed by 25% of the Population
  • 4.5 Private Insurance Market Growing but Costs are Rising
  • 4.6 New Drug Price Adjustment System Introduced
  • 4.7 RENAME Drug Reimbursement System and the Farmácia Popular
  • 4.8 Extensive Network of Pharmacies in Brazil
  • 4.9 Wholesale and Retail Sectors Undergoing Consolidation
  • 4.10 Panpharma is the Top Wholesale Distributor
  • 4.11 Profarma is the Largest Mixed Distributor
  • 4.12 Raia Drogasil is the Leader in the Retail Sector
  • 4.13 Spending on Marketing Approaches $5bn

5. Major Differences in Healthcare Between Regions

  • 5.1 Size and Prosperity of Different Regions
  • 5.2 South-East is the Richest and Most Populous Region
  • 5.3 South Has the Second Highest GDP
  • 5.4 North-East Has the Second Highest Pharmaceutical Market Share
  • 5.5 North is the Largest and Poorest Region
  • 5.6 Mid-West is a Landlocked Region Housing the Nation's Capital

6. Product Segments in the Brazilian Pharmaceutical Market 2016-2027

  • 6.1 Forecasts for the Originator, Generic and OTC Segments 2016-2027
  • 6.2 Originator Segment Will be Overtaken by Generics
    • 6.2.1 Product Development Partnerships to Reduce Costs
    • 6.2.2 Originator Drugs Threatened by 35% Cheaper Generics
  • 6.3 Generics Drug Segment Forecast 2016-2027 - Continued Rapid Growth
    • 6.3.1 Rapid Expansion of Generic Segment
    • 6.3.2 Generic Companies Aiming for 45% Market Share
    • 6.3.3 Similares Drugs Face Same Pricing Rules as Generics
    • 6.3.4 Counterfeit Drugs Account for 20% of the Market
    • 6.3.5 National Drug Security System to Tackle Counterfeit Drugs
    • 6.3.6 Challenges for the Brazilian Generics Market
  • 6.4 Brazilian Biologics Market
    • 6.4.1 Biosimilars Market to Double in Size by 2017
    • 6.4.2 BiocadBrazil Brings More Biosimilars to Brazil
  • 6.5 OTC Drug Segment Forecast 2016-2027
    • 6.5.1 Analgesics and Multivitamins Favoured by Brazilians
    • 6.5.2 One Sixth of Population Buy Multivitamins
    • 6.5.3 Restrictions on OTC Products Reversed
    • 6.5.4 Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas of the Brazilian Market, 2016-2027

  • 7.1 Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2016-2027
  • 7.2 The Rise of Non-Communicable Diseases
  • 7.3 Market Forecast for CNS Conditions 2016-2027
    • 7.3.1 CNS Conditions Currently the Largest Therapeutic Area
    • 7.3.2 Domestic Companies Target Generic and OTC CNS Products
    • 7.3.3 Foreign Companies Target Analgesics Market
    • 7.3.4 One Fifth of Brazilians Have Suffered Depression
    • 7.3.5 CNS Conditions: Drivers and Restraints
  • 7.4 Market Forecast for Cardiovascular Therapeutic Area, 2016-2027
    • 7.4.1 Rate of Cardiovascular Disease Expected to Triple
    • 7.4.2 Almost One Quarter of the Population are Hypertensive
    • 7.4.3 Statin Revenues Decline with Loss of Patent Protection
    • 7.4.4 Domestic and International Companies Compete in CVS
    • 7.4.5 Cardiovascular Opportunities and Challenges
  • 7.5 Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2016-2027
    • 7.5.1 High Prevalence of Diabetes and GI Conditions
    • 7.5.2 Low Awareness of Diabetes Amongst Population
    • 7.5.3 Drive for Domestic Production of Insulin
    • 7.5.4 EMS's Generic Esomeprazole an Important Addition
    • 7.5.5 Capturing the Gastrointestinal/Metabolic Disease Opportunity
  • 7.6 Market Forecast for Oncology Therapeutic Area, 2016-2027
    • 7.6.1 Cancer Treatment to Become the Leading Therapeutic Area
    • 7.6.2 Increased Coverage of Cancer Care by Private Health Insurance Providers
    • 7.6.3 What are the Commonest Cancers in Brazil?
    • 7.6.4 Biosimilars Will Help Widen Access to Cancer Drugs
    • 7.6.5 Cristália and Libbs Amongst Leading Oncology Companies
    • 7.6.6 Promising Potential of the Oncology Therapeutic Area
  • 7.7 Market Forecast for Infectious Diseases Therapeutic Area, 2016-2027
    • 7.7.1 Vaccines and Antibiotics Lead Therapeutic Area
    • 7.7.2 Brazil Increasingly Manufacturing its Own Vaccines
    • 7.7.3 First Vaccination Programme Against Dengue Fever
    • 7.7.4 Free Access to HIV Care Despite Concerns About Patent Protection
    • 7.7.5 Chagas Disease and Other Tropical Infections
    • 7.7.6 Long-Term Threat from Zika Virus Epidemic
    • 7.7.7 Importance of Infectious Diseases Compared to Chronic Diseases
  • 7.8 Market Forecast for Other Therapeutic Areas, 2016-2027

8. Domestic Companies in the Brazilian Market

  • 8.1 The Top Ten Domestic Pharmaceutical Companies in 2016
  • 8.2 Multinational Companies Still Own the Majority of the Market
  • 8.3 Domestic Sector Actively Encouraged by Government
  • 8.4 Domestic Firms Control 70% of Generics Market
  • 8.5 EMS: Brazil's Leading Pharmaceutical Company
    • 8.5.1 Separate Divisions for Different Drug Categories
    • 8.5.2 Full Production and R&D Capability
    • 8.5.3 Legrand and Germed are Key Subsidiaries
    • 8.5.4 Targeted Expansion Overseas
  • 8.6 Hypermarcas: Market Leader in OTC and Branded Generics
    • 8.6.1 Neo Quimica: Ranked Third in the Generics Segment
    • 8.6.2 Subsidiaries Include Mantecorp and Brainfarma
  • 8.7 Medley: Generics Company Owned by Sanofi
  • 8.8 Aché: A Major Acquisition Target in Brazil
    • 8.8.1 Anti-Inflammatory Acheflan Was First Drug Developed in Brazil
    • 8.8.2 Involvement of Aché in Acquisitions Process
    • 8.8.3 Part of Bionovis Collaboration
  • 8.9 Eurofarma: Fourth Largest Domestic Company with Plans to Cover 90% of Latin America
    • 8.9.1 Policy to Make Acquisitions in Latin America
  • 8.10 Teuto Operates Largest Pharmaceutical Complex in Latin America
    • 8.10.1 Melcon Partnership and Other Growth Strategies for Teuto
  • 8.11 Biolab Farmaceutica Leads Cardiology Drugs Market
    • 8.11.1 Partnering with German and Indian Companies
    • 8.11.2 Current Pipeline and Product Launches
  • 8.12 Cristalia: Largest Producer of Anaesthetics in Latin America
    • 8.12.1 Approval from ANVISA to Produce Biosimilar Drugs
    • 8.12.2 Leader in API Manufacturing
    • 8.12.3 Involved in One Third of all PDPs
  • 8.13 Libbs: Key Player in Cancer Treatment
    • 8.13.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
  • 8.14 União Quimica: Huge Annual Production Capacity
    • 8.14.1 Agreement with Novartis and Possible Public Offering in 2015
  • 8.15 Other Domestic Players Include Laboratório Daudt Oliveira and Hebron
  • 8.16 Biosimilar Collaborations
    • 8.16.1 Bionovis: Conglomerate Developing 8 Biosimilars
    • 8.16.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
    • 8.16.3 Other Biotech Players Include Biomm and Innova
    • 8.16.4 Fiocruz: At the Heart of Multiple PDPs
    • 8.16.5 ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market

  • 9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2016
  • 9.2 Notable M&A Activity
  • 9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
    • 9.3.1 Group Companies Include Sanofi Pasteur and Genzyme
    • 9.3.2 Inventory Mishandling and Dip in 2013 Results
  • 9.4 Novartis: Only Multinational to Produce APIs in Brazil
    • 9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
    • 9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
    • 9.4.3 Investment in Expansion Plans
  • 9.5 Roche: No Regrets About Staying in Brazil
    • 9.5.1 Oncology Opportunity and Herceptin Pricing
  • 9.6 Merck & Co. - Long-Standing Presence in the Brazilian Market
    • 9.6.1 Five Factories and Five Broad Therapeutic Areas
    • 9.6.2 Gardasil Added to SUS in 2013
    • 9.6.3 Joint Venture with Eurofarma and Cristalia
  • 9.7 Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers
    • 9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
  • 9.8 Takeda: Expanding its Brazilian Business
    • 9.8.1 Acquisitions of Nycomed and Multilab
  • 9.9 Bayer: Brazil is its Fifth Largest Market
    • 9.9.1 OTC is a Major Focus in Brazil
  • 9.10 AstraZeneca Targets Latin America
    • 9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
  • 9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
    • 9.11.1 Looking to Acquire OTC Brands
    • 9.11.2 Technology Transfer Deal for Parkinson's Disease
  • 9.12 Merck KGaA Signed PDP with Bionovis for 8 Biosimilars
    • 9.12.1 Two Divisions and Multiple Therapeutic Fields
  • 9.13 Other Notable Multinationals in Brazil
    • 9.13.1 GSK: Vaccines and Technology Transfer Opportunities
    • 9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
    • 9.13.3 Abbott: Generics and Diagnostics-Led Growth Strategy
    • 9.13.4 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
    • 9.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
    • 9.13.6 Baxter Entering Haemophilia Market Via Technology Transfer
    • 9.13.7 Johnson & Johnson: Focusing on Consumer Health and Commodities
    • 9.13.8 BiocadBrazil Farmaceutica
    • 9.13.9 Amgen Signals Brazilian Intent with Bergamo Acquisition
    • 9.13.10 Gilead, Novo Nordisk, Biogen, UCB and Meizler
    • 9.13.11 Other Top Japanese Companies Trail Behind Takeda in Brazil
  • 9.14 Will Multinational Generics Leaders Compete in Brazil?
    • 9.14.1 Teva Targets Brazil
    • 9.14.2 Mylan Acquires Agila to Boost Brazilian Strategy
    • 9.14.3 Actavis May Target Brazil
    • 9.14.4 Ranbaxy and Daiichi Sankyo
    • 9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
    • 9.14.6 Valeant: M&A Drive into the Market
  • 9.15 Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2017

  • 10.1 Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis
    • 10.1.1 A Crucial Market for the Pharmaceutical Industry
    • 10.1.2 Government Regulation Remains an Issue
    • 10.1.3 One of the Highest Pharmaceutical Tax Rates in the World
    • 10.1.4 Room to Expand in Therapeutic Areas and Geographic Regions
    • 10.1.5 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
  • 10.2 Social, Technological, Economic and Political (STEP) Analysis
    • 10.2.1 Large and Ageing Population Eager to Buy Medicines
    • 10.2.2 Shortcomings of Brazil's Healthcare System
    • 10.2.3 Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT
    • 10.2.4 Can Economic Growth Keep Pace with Healthcare Costs?
    • 10.2.5 Political Environment Acts as Decisive Influence on the Market
    • 10.2.6 Will BREXIT Affect Free Trade Negotiations with the EU?

11. Conclusions from Our Research and Analysis

  • 11.1 Growth of Brazil's Pharmaceutical Market Will Outstrip That of More Developed Countries
  • 11.2 Generics Will be the Main Growth Driver
  • 11.3 Technology Transfer Boosts Domestic Production of Originator Drugs
  • 11.4 Generics Market Provides Alternative Option for Multinationals
  • 11.5 Oncology Will be the Main Growth Area in the Brazilian Pharmaceutical Market
  • 11.6 Concluding Comments

Appendices

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Brazilian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 2.2 Brazilian Pharmaceutical Market by Segment: Revenue ($bn) and Market Share (%), 2016
  • Table 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2016
  • Table 2.4 Brazilian Pharmaceutical Market: Top Ten Companies - Revenue ($bn) and Market Share (%), 2016
  • Table 3.1 World' s Largest Pharmaceutical Markets, Revenue ($bn) and Market Share (%), 2016
  • Table 3.2 Top Latin American Pharmaceutical Markets: Revenue ($bn) and Market Share (%), 2016
  • Table 3.3 Pharmerging Countries
  • Table 4.1 Members of FenaSaúde (in Portuguese, with English in brackets), 2017
  • Table 6.1 Originator Drug, Generic Drug and OTC Drug Segments Forecast: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2022
  • Table 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2027
  • Table 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2016-2027
  • Table 6.5 Originator Drug Segment: Revenue Forecasts ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 6.6 Selected Technology Transfer Agreements in Brazil 1985-2013
  • Table 6.7 Generic Drug Segment: Revenue Forecasts ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 6.8 OTC Drug Segment: Revenue Forecasts ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.1 Brazilian Pharmaceutical Market - Therapeutic Areas: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2022
  • Table 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2027
  • Table 7.4 CNS Therapeutic Area: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.5 Cardiovascular Therapeutic Area: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.6 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.7 Oncology Therapeutic Area: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.8 Infectious Diseases Therapeutic Area: Revenue ($bn, Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 7.9 Other Therapeutic Areas: Revenue ($bn), Market Share (%), AGR (%), CAGR (%), 2016-2027
  • Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenue ($bn) and Market Share (%), 2016
  • Table 8.2 EMS Overview
  • Table 8.3 Hypermarcas Overview
  • Table 8.4 Medley Overview
  • Table 8.5 Aché Overview
  • Table 8.6 Eurofarma Overview
  • Table 8.7 Teuto Overview
  • Table 8.8 Biolab Farmacêutica Overview
  • Table 8.9 Biolab Farmacêutica Pipeline, 2016
  • Table 8.10 Cristalia Overview
  • Table 8.11 Libbs Overview
  • Table 8.12 União Química Overview
  • Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2016
  • Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
  • Table 9.3 Sanofi Overview
  • Table 9.4 Novartis Overview
  • Table 9.5 Roche Overview
  • Table 9.6 Merck & Co. Overview
  • Table 9.7 Pfizer Overview
  • Table 9.8 Takeda Overview
  • Table 9.9 Bayer Overview
  • Table 9.10 AstraZeneca Overview
  • Table 9.11 Boehringer Ingelheim Overview
  • Table 9.12 Merck KGaA Overview
  • Table 10.1 Brazilian Pharmaceutical Market: SWOT Analysis 2017
  • Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2016
  • Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2017

List of Figures

  • Figure 1.1 Product Segments of Brazilian Pharmaceutical Market
  • Figure 1.2 Main Therapeutic Areas Within Brazilian Pharmaceutical Market
  • Figure 2.1 Brazilian Pharmaceutical Market: Revenue ($bn) 2016-2027
  • Figure 2.2 Brazilian Pharmaceutical Market by Segment: Market Share (%), 2016
  • Figure 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2016
  • Figure 2.4 Brazilian Pharmaceutical Market: Top Ten Companies - Market Share (%), 2016
  • Figure 3.1 Top Ten Global Economies, 2017
  • Figure 3.2 Top Ten Global Economies, 2030
  • Figure 3.3 World's Largest Pharmaceutical Markets by Market Share (%), 2016
  • Figure 3.4 Top Latin American Pharmaceutical Markets: Market Share (%), 2016
  • Figure 3.5 BRIC Countries Pharmaceutical Market Revenue ($bn), 2016
  • Figure 4.1 Public Healthcare Versus Private Healthcare: Market Share (%), 2017
  • Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013
  • Figure 5.2 Brazil: Regional Population Shares (%), 2013
  • Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012
  • Figure 5.4 Brazilian GDP Shares (%) by Region, 2013
  • Figure 6.1 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2022
  • Figure 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2027
  • Figure 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2016-2027
  • Figure 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn), 2016,2022, 2027
  • Figure 6.5 Originator Drug Segment: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2017
  • Figure 6.7 Generic Drug Segment: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.8 Drivers and Restraints for Generic Drugs, 2017
  • Figure 6.9 Brazilian Biologics Market Breakdown: Revenue ($bn) and Market Share (%), 2016
  • Figure 6.10 Brazilian Biologics Market Breakdown: Revenue ($bn), 2016, 2021 and 2027
  • Figure 6.11 OTC Drug Segment: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 6.12 Drivers and Restraints for OTC Drugs, 2017
  • Figure 7.1 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2022
  • Figure 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2027
  • Figure 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue Forecasts ($bn), 2016-2027
  • Figure 7.4 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn), 2016, 2022, 2027
  • Figure 7.5 CNS Therapeutic Area: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.6 Drivers and Restraints for CNS Conditions, 2017
  • Figure 7.7 Cardiovascular Therapeutic Area: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2017
  • Figure 7.9 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.10 Drivers and Restraints for Gastrointestinal/Metabolic Therapy Area, 2017
  • Figure 7.11 Oncology Therapeutic Area: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.12 Estimated Cancer Incidence for Males in Brazil, 2016
  • Figure 7.13 Estimated Cancer Incidence for Females in Brazil, 2016
  • Figure 7.14 Drivers and Restraints for the Oncology Therapeutic Area, 2017
  • Figure 7.15 Infectious Diseases Therapeutic Area: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 7.16 Drivers and Restraints for the Infectious Disease Therapeutic Area 2017
  • Figure 7.17 Other Therapeutic Areas: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Market Share (%), 2016
  • Figure 8.2 Aché Product Portfolio Breakdown (%), 2013
  • Figure 9.1 Leading Multinational Companies in the Brazilian Market: Market Shares (%), 2016
  • Figure 11.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn) and AGR (%), 2016-2021
  • Figure 11.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn) and AGR (%), 2021-2027
  • Figure 11.3 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2016-2021
  • Figure 11.4 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2021-2027
  • Figure 11.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenue ($bn), 2016
  • Figure 11.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2016-2021
  • Figure 11.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2021-2027

Companies Listed

  • Abbott Laboratories
  • Aché Laboratórios Farmacêuticos S.A
  • Actavis PLC
  • Agila Specialties Private Ltd
  • Allianz Saúde
  • Alteogen Inc
  • AmerisourceBergen Corporation (ABC)
  • Amgen Inc
  • Antaris Consulting
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Athos Farma SA
  • Axis Biotec Brasil
  • Baxter International Inc
  • Bayer AG
  • Bergamo Ltda
  • Beth Israel Hospital
  • Billi Farmacêutica
  • Biocad
  • BiocadBrazil Farmaceutica
  • Biocon Limited
  • Biolab Emcure Farmaceutica Comercial Ltda
  • Biolab Farmaceutica
  • Bio-Manguinhos (Instituta de Tecnologia em Imunobiologicos)
  • Biomm SA
  • Bionovis SA
  • Biovail Corporation
  • Boehringer Ingelheim GmbH
  • Boiron
  • Brainfarma Indústria Química e Farmacêutica
  • Brasil Pharma
  • Brazil Produtos Roche Químicos e Farmacêuticos
  • Bristol-Myers Squibb (BMS)
  • BTG Pactual
  • Bunker Industria Farmaceutica
  • Butantan Institute
  • Câmara de Regulação do Mercado de Medicamentos (CMED)
  • Care Plus Medicina Assistencial S/S Ltda
  • Ceitec SA
  • Celesio AG
  • Chemo Group
  • Claris Lifesciences Ltd
  • Conselho Federal de Farmácia
  • Conselho Federal de Medicina (CFM)
  • Corporacion Infarmasa SA
  • Cosmed Industria de Cosmeticos e Medicamentos
  • Cristália
  • CVS Pharmacy
  • Daiichi Sankyo
  • Delta
  • Dimed SA
  • Distribuidora Farmacêutica Panarello Ltda
  • DM Industria Farmacêutica Ltda
  • Drogaria Sao Paulo
  • Drogarias DPSP SA
  • Drogarias Farmais
  • Drogarias Pacheco
  • Drogarias Tamoio
  • Drogasil SA
  • Eisai Co Ltd
  • Eli Lilly & Co
  • Emcure Pharmaceuticals Ltd
  • Empresas Andromaco
  • EMS
  • Eurofarma
  • Eurofarma Argentine
  • Eurofarma Chile
  • Eurofarma Uruguay
  • Everis Group
  • F. Hoffmann-La Roche AG
  • Farmácia Ben
  • Farmácia Popular
  • Farmacias Mais Econômica
  • Farmácias Guararapes
  • Farmalife
  • Farmanguinhos (Instituto de Tecnologia em Farmacos)
  • Farmindustria SA
  • Federação Nacional de Saúde Suplementar (FenaSaúde)
  • Forest Laboratories Inc
  • Fundação Oswaldo Cruz (FioCruz)
  • Fundação Ezequiel Dias (Funed)
  • Genzyme Corporation
  • Germed Pharma
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC (GSK)
  • Glenmark Pharmaceuticals
  • Golden Cross
  • Grünenthal Group
  • Grupo Amil Saúde
  • Grupo Bradesco Saúde
  • Grupo Cimed
  • Grupo Notre Dame Intermédica Saúde
  • Grupo SulAmérica Saúde
  • Hapvida Assistência Médica
  • Health Canada
  • Hebron
  • Hemobrás
  • Horizon Pharma PLC
  • Hypermarcas
  • IMA Laboratories
  • Indar Institute
  • Indian Council of Medical Research
  • Innova Pharma
  • Janssen
  • Johnson & Johnson
  • Kantar Health
  • Laboratório Daudt Oliveira
  • Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE)
  • Laboratório Prata
  • Laboratório Sanobiol
  • Laboratório Teuto
  • Laboratorio Volta
  • Laboratório Tiaraju
  • Laboratórios Gautier
  • Laboratórios Klinger Do Brasil
  • Laboratorios Laprin S.A
  • Lazard
  • Legrand Pharma Industria Farmaceutica Ltda
  • Libbs Biotec
  • Libbs Farmacêutica Ltda
  • Luper Indústria Farmacêutica
  • mAbxience
  • Mantecorp Quimica Industria e Farmaceutica Ltda
  • Médecins sans Frontières (MSF)
  • Medley Farmacêutica
  • Meizler Biopharma SA
  • Melcon Indústria Farmacêutica SA
  • Merck & Co., Inc
  • Merck KGaA
  • Merck Serono
  • Mercosur
  • Merial
  • Merz Pharma GmbH & Co. KGaA
  • Metlife Exclusivamente Odontológicos
  • Metropolitan Life Insurance Company
  • Minas Gerais State Department of Health
  • Moksha8
  • Multilab Industria e Comerci de Produtos Farma
  • Mundipharma International Ltd
  • Mylan NV
  • Nature's Plus Farmacêutica Ltda
  • NeoQuimica
  • Nortis Farmaceutica Ltda
  • Novartis AG
  • Novartis Biociências
  • Novo Nordisk A/S
  • Nycomed
  • OdontoPrev
  • Omint Serviços de Saúde
  • Oncoprod
  • Optimer Pharmaceuticals Inc
  • Orygen Biotecnologia
  • Otsuka Pharmaceutical Co Ltd
  • Panpharma
  • Pasteur Institute
  • Pele Nova Biotecnologia SA
  • Pfizer Inc
  • PharmaPraxis
  • Porto Seguro - Seguro Saúde
  • Probiomed SA de CV
  • Probiotica Laboratórios Ltda
  • Procter and Gamble Co
  • Profarma
  • Profarma Specialty SA
  • Protalix BioTherapeutics Inc
  • Quesada Farmacêutica SA
  • Quintiles Inc
  • Raia Drogasil
  • Raia SA
  • Ranbaxy Laboratories Ltd
  • Reckitt Benckiser Group PLC
  • Roche Diagnostica Brasil
  • Rosário
  • Sabin Vaccine Institute
  • Sandoz Brazil
  • Sandoz do Brasil Indústria Farmacêutica
  • Sanofi
  • Sanofi Pasteur SA
  • Sant'Ana S.A. Drogaria Farmácias
  • Santa Cruz Distribuidora de Medicamentos
  • Savicevic Participacoes SA
  • SC Participações Empresariais Ltda
  • Schwarz Pharma
  • Serum Therapeutic Institute
  • Shasun Pharmaceuticals Ltd
  • Sinclair IS Pharma PLC
  • Sindusfarma
  • State Pharmaceutical Laboratory of Pernambuco (LAFEPE)
  • Strides Arcolab
  • Sun Pharmaceutical Industries Ltd
  • Supera Farma Laboratorios
  • Takeda Pharmaceutical Company Ltd
  • Telefônica Digital
  • Teva Pharmaceutical Industries Ltd
  • The Walgreen Company
  • TKS Farmacêutica Ltda
  • Torrent Pharmaceuticals Ltd
  • UCB Pharma SA
  • União Química Farmacêutica Nacional SA
  • Valeant Pharmaceuticals International Inc
  • Warc
  • Watson Pharmaceuticals Inc
  • Wockhardt Ltd
  • Yasuda Marítima Saúde Seguros SA
  • Zydus Cadila

List of Organizations Mentioned in the Report

  • Agência Nacional de Saúde Suplementar (ANS)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • AMB (Brazilian Medical Association)
  • American Diabetes Association (ADA)
  • Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)
  • Associação Brasileira de Reabilitação de Coluna (Brazilian Association of Back Rehabilitation)
  • Associação da Industria Farmacêutica de Pesquisa (Interfarma)
  • Associação Nacional de Assistencia ao Diabetico (ANAD)
  • Bill & Melinda Gates Foundation
  • Brazilian Institute of Tax Planning
  • Brazilian National Bank for Economic and Social Development (BNDES)
  • Brazilian National Institute of Social Security (INSS)
  • British Medical Journal (BMJ)
  • Centre for Economics and Business Research (CEBR)
  • European Medicines Agency (EMA)
  • Federal Court of Rio de Janeiro
  • Food and Drug Administration (FDA)
  • Health Network Formation and Quality Improvement Project (QualiSUS)
  • Hospital das Clínicas, São Paulo
  • Hospital Israelita Albert Einstein
  • Hospital Santa Catarina
  • Institute for Health Insurance (IESS)
  • Instituto Brasileiro de Geografia e Estatística(IBGE)
  • Instituto de Estudos de Saúde Suplementar (IESS)
  • Instituto de Tecnologia do Paraná (TECPAR)
  • Instituto Terapeutico Delta
  • Instituto Vital Brazil
  • Kenya Medical Research Institute
  • Ministry of Health of Malaysia
  • Ministry of Health, Brazil
  • National Institutes of Health
  • Organisation for Economic Co-operation and Development (OECD)
  • Pan American Health Organization
  • Pró-Genéricos (the Brazilian Association of Generic Drug Industries)
  • São Paulo Stock Exchange
  • Sindicato do Comércio Atacadista de Drogas, Medicamentos, Correlatos, Perfumarias,
  • Cosmeticos e Artigos de Toucador no Estado de São Paulo (SINCAMESP)
  • Sistema Único de Saúde (SUS)
  • UERJ (Universidade do Estado do Rio de Janeiro)
  • UNICAMP (Universidade Estadual de Campinas)
  • Unimed Seguros Saúde
  • University of São Paulo
  • University of Texas
  • Walter Reed Army Institute of Research
  • World Bank
  • World Health Organization (WHO)
Back to Top